Effects Of Selective Bile Duct Embolization And Selective Portal Vein Embolization On Tumor And None-embolization Liver In Rats With Transplanted Liver Cancer

BackgroundLiver resection is the preferred and the most effective treatment of liver cancer. About 45% of primary and secondary liver cancer need extended liver resection to achieve radical resection.Postoperative residual liver insufficiency is an important factor caused postoperative complications such as liver failure. In the liver cancer patients, resection of 60% of functional liver with primary damage, resection of 75% of normal functional liver, was significantly higher post-operative complications. Portal vein embolization can make embolization side lobe atrophy and contralateral lobe hyperplasia; this will promote opportunities of patients, who can not accept surgical resection origin. Since Makkudi successed to use PVE on a patient with hilar cholangiocarcinoma before major hepatectomy on 1990, PVE have been used in clinical in Japan, Europe and the United States and other places. In recent years, some scholars have found that patients who accept PVE, tumor growth will increase rapidly, no matter in embolization lobe or none-embolization lobe, and its impact on survival has not conclusive. For this reason, the clinical need a more safe and effective way to achieve the purpose to increase the remaining liver volume.Atrophy and hypertrophy syndrome of liver is common in clinical, it is caused by bile duct or portal vein obstruction or combination of factors. We assume that the selective bile duct embolization cause liver atrophy in embolization regional and none-embolization liver compensatory hypertrophy, thereby increasing the safety of expansion liver resection. At present, scholars have conducted a study that the selective bile duct embolization can be safe and effective induced liver atrophy and hypertrophy syndrome, in addition, scholars believe that bile duct embolization have a certain therapeutic effect on hepatocellular carcinoma. On this basis, in this study, we will to investigate the effect of selective bile duct embolization and selective portal vein embolization on tumor and none-embolization liver tissue, by means of to provide a new method for clinical..Materials and Methods60 Sprague-Dawley rats were implanted Walker-256 carcinoma in their livers, and were divided into 3 groups randomly. Respectively selective portal vein embolization, selective bile duct embolization and laparotomy alone, after embolization in 1,2,3,4 weeks each executed five rats, testing in general, histology, tumor size, liver function, tumor tissue Ki67 expression were detected by immunohistoch-emistry, antiangiogenetic effects were assessed by CD31 immunostaining.ResultsThe rats serum AST,ALT and none-embolization liver volume were rise in rats treated by selective portal vein embolization and selective bile duct embolization(P<0.01 or P<0.05). Selective portal vein embolization in rats liver volume and Ki67-positive rate of cancer than the other two groups (P<0.05), selective bile duct embolization group and control group no statistically significant difference (P> 0.05). There was no significant difference of the intratumoral microvessel density (MVD) among 3 groups (P>0.05) ConclusionSelective portal vein embolization and selective bile ducts embolization were able to increase none-embolization liver volume, selective portal vein embolization have better efficacy. Selective portal vein embolization can promote rat transplantation liver tumor growth, selective bile duct embolization do not influence rat transplantation liver tumor growth.